View: Logistics is likely to be the biggest problem in India’s vaccination drive
SECTIONS
View: Logistics is likely to be the biggest problem in India’s vaccination driveBy Abheek Barua, ET CONTRIBUTORS
Last Updated: Dec 31, 2020, 08:59 AM IST
Share
Synopsis
A simple comparison would illustrate the enormity of the challenge. India already has a robust inoculation programme in place under its universal immunisation programme for children. The size of the Covid drive will be roughly five times that of the existing programme.
Agencies
The ultimate success or failure of India’s Covid vaccination drive will depend on its ability to reach its villages.
How will Oxford vaccine be made in India? Exclusive peek inside Serum Institute s Covishield plant
How will Oxford vaccine be made in India? Exclusive peek inside Serum Institute s Covishield plant
India Today TV s Rahul Kanwal visited the Serum Institute in Pune where millions of Covishield viles are being produced, packaged and stored as we speak. The institute’s CEO Adar Poonawalla took Rahul Kanwal for an exclusive walkabout around the Covishield factory to show and explain that process.
advertisement
UPDATED: January 3, 2021 12:59 IST
SII CEO Adar Poonawalla took India Today TV’s Rahul Kanwal for an exclusive tour of the factory making Covishield – the Oxford Covid-19 vaccine
Nepal seeks to procure Covid vaccine from India
By IANS |
Published on
Wed, Dec 30 2020 17:27 IST |
0 Views
China s Covid vaccine is caught in controversy. Image Source: IANS News
Kathmandu, Dec 30 : The Nepal government has written to the Indian government, requesting for procurement of Covid-19 vaccine to inoculate around 20 per cent of the Nepali population.
The Indian government is procuring the jabs manufactured in its own country to vaccinate its people against Covid-19.
The Ministry of Foreign Affairs recently wrote to the Indian government, requesting for the supply of the vaccines that would suffice the need for the 20 per cent of the population.
URL copied
AstraZeneca-Oxford vaccine not ready for approval: European watchdog
As the country awaits the UK s approval to the AstraZeneca-Oxford vaccine before giving nod for Emergency Use Authorisation to its Indian counterpart developed by Pune-based Serum Institute of India (SII), a top European drug official has claimed that the vaccine is not even ready for a conditional approval at the moment.
Noel Wathion, number two at the European Medicines Agency, told Belgian newspaper Het Nieuwsblad on Tuesday that the approval for AstraZeneca-Oxford vaccine is still unthinkable and Europe is not going to approve the vaccine with winning formula for the time being.
Expert Panel To Reconvene On Covid Vaccine Nod On January 1
Panel to brainstorm on emergency use authorisation applications by the SII and Bharat Biotech s
PTI 30 December 2020 PTI 2020-12-30T21:54:06+05:30 Expert Panel To Reconvene On Covid Vaccine Nod On January 1 outlookindia.com 2020-12-30T21:56:54+05:30
Also read
An expert panel in the Central Drugs Standard Control Organisation (CDSCO) that met on Wednesday to consider emergency use authorisation applications by the SII for the Oxford Covid-19 vaccine and Bharat Biotech s Covaxin will reconvene on January 1 to further deliberate on the matter.
The Subject Expert Committee (SEC) on Covid-19 deliberated and analysed the additional data and information submitted by Serum Institute of India (SII) and Bharat Biotech.